Ross is a principal on the Biotech Private Investments Team. He is responsible for deal flow and due diligence on private investments in biotechnology companies, including analysis of therapeutic hypothesis and company fundamentals. 

Prior to joining Wellington Management in 2022, Ross worked as a senior associate at Novo Ventures (2020 – 2022) and the T1D Fund (2017 – 2020), focused on diligence of private therapeutics companies. Previously, he was a consultant with the Boston Consulting Group, supporting pharmaceuticals and medical technology clients (2016 – 2017). 

Ross received his MD from the Stanford University School of Medicine (2011 – 2015) where he was a fulbright scholar working on global health in Peru (2013 – 2014). He received his BS in human biology from the University of California in San Diego (2007 – 2011).